Results 81 to 90 of about 657,649 (153)

NTRK fusion-positive cancers and TRK inhibitor therapy

, 2018
NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types.
Drilon, Alexander, Maurizio Scaltriti, Alexander Drilon, Scaltriti, Maurizio, Cocco, Emiliano, Emiliano Cocco   +5 more
core   +1 more source

oxazin-7(8H)one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants

, 2022
Tropomyosin receptor kinases (TrkA, TrkB, and TrkC) are attractive therapeutic targets for multiple cancers. Two first-generation small-molecule Trks inhibitors, larotrectinib and entrectinib, have just been approved to use clinically.
Shulei Pan (1590091), Zhiling Pan (12004229), Huachao Bin (12004226), Shengyong Yang (2123410), Zhiling Pan, Shengyong Yang, Yang Liu, Tianqi Wang (4093009), Chenyu Tian, Bo Mu, Linli Li, Wei Yang, Shulei Pan, Wei Yang (109917), Jinshan Nan (12004223), Xinling Luo (11910086), Falu Wang (12004232), Falu Wang, Chenyu Tian (7900979), Qiao Huang (4386955), Yang Li (7082), Yang Liu (4829), Qiao Huang, Liting Zhang (2883890), Liting Zhang, Huachao Bin, Yang Li, Jinshan Nan, Bo Mu (396892), Xinling Luo, Tianqi Wang, Linli Li (436139)   +31 more
core   +1 more source

Exploring New Therapeutic Targets in NSCLC: Unraveling the Interplay Between NTRK and PD-L1 Expression

Journal of Respiration
Background: Precision medicine has introduced immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) as key therapies for lung cancer.
Jair Gutierrez-Herrera, Maria Angeles Montero-Fernandez, Georgia Kokaraki, Luigi De Petris, Raul Maia Falcão, Ricardo Guijarro, Simon Ekman, Cristian Ortiz-Villalón   +7 more
doaj   +1 more source

Preclinical Evaluation of the Oral Toxicity, Genotoxicity, and Safety Pharmacology of LPM4870108, a Novel Potent Tropomyosin Receptor Kinase Inhibitor

Pharmacology Research & Perspectives
Tropomyosin receptor kinase (Trk) inhibitors are an essential class of anticancer drugs treating NTRK gene fusions‐positive cancer. However, the potential for the emergence of on‐target resistance suggests newer Trk inhibitors with low drug resistance ...
Xiaochen Zhang, Baiyang Yuan, Chunmei Li, Hongbo Wang, Shujuan Wei, Jingwei Tian, Sijin Duan   +6 more
doaj   +1 more source

Neuroligin-1 dependent phosphotyrosine signaling in excitatory synapse differentiation

Frontiers in Molecular Neuroscience
IntroductionThe synaptic adhesion molecule neuroligin-1 (NLGN1) is involved in the differentiation of excitatory synapses, but the precise underlying molecular mechanisms are still debated.
Zsófia Szíber, Adèle Drouet, Magali Mondin, Florian Levet, Florian Levet, Olivier Thoumine   +5 more
doaj   +1 more source

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy

ESMO Gastrointestinal Oncology
Background: Currently, mismatch repair deficient/microsatellite instable (dMMR/MSI) status constitutes a validated predictive marker of response to immune checkpoint inhibitors (ICIs) in patients with metastatic colorectal cancer (mCRC).
M. Svrcek, A. Cayre, T. Samaille, R. Colle, L. Mas, P. Bourgoin, E. Guillerm, R. Cohen, F. Penault-Llorca, T. André, N. Radosevic-Robin   +10 more
doaj   +1 more source

Three locally invasive infantile fibrosarcoma cases treated with larotrectinib

The Turkish Journal of Pediatrics
Background. Infantile fibrosarcoma is a rapidly growing soft tissue tumor, often managed by surgical resection, with chemotherapy and radiotherapy as additional options.
Hikmet Gülşah Tanyıldız, Yasin Yılmaz, Doğa Dalay, Şifa Şahin, Serap Karaman, Ayşegül Ünüvar, Zeynep Karakaş, Deniz Tuğcu   +7 more
doaj   +1 more source

Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report. [PDF]

Medicine (Baltimore), 2023
Kubota Y, Kawano M, Iwasaki T, Itonaga I, Tsumura H, Kaku N, Tanaka K.   +6 more
europepmc   +1 more source

Tropomyosin receptor kinase inhibitors in the management of sarcomas

, 2020
PURPOSE OF REVIEW: Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours.
Robin L. Jones, Huang, PH, Loong, HH, Wilding, CP, Paul H. Huang, Herbert H. Loong, Christopher P. Wilding, Jones, RL   +7 more
core   +1 more source

Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors. [PDF]

JCO Precis Oncol, 2023
Chen MF, Yang SR, Shia J, Girshman J, Punn S, Wilhelm C, Kris MG, Cocco E, Drilon A, Raj N.   +9 more
europepmc   +1 more source